A Phase 3 interventional study of Medi-546 and Placebo in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Active, not recruiting at 140 sites in 15 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 9 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 9th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2021.
This study's enrollment of 367 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2021, is one of 9 in phase 3, reaches primary completion later than 0 of the 24 other live ones, and was the 15th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of a subcutaneous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral glucocorticoids, antimalarial, and/or immunosuppressants. The study will be performed in adult participants of 18 to 70 years of age.
Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed subcutaneous dose of anifrolumab or placebo administered once weekly via an accessorized prefilled syringe and with the primary endpoint evaluated at Week 52. Subjects who complete Week 52 may enter into open-label extension (OLE). All patients who enter the OLE Period will receive a fixed subcutaneous dose of anifrolumab for up to 52 weeks. Study intervention will be administered SC via an accessorised prefilled syringe (aPFS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
BILAG2004 with at least 1 of the following:
Exclusion Criteria:
History of cancer, apart from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Solution for injection in aPFS
Drug: Medi-546
Solution for injection in aPFS
Drug: Placebo
Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
Solution for injection in aPFS
British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
BICLA response is a composite binary endpoint whereby responders are defined by meeting all of the following criteria: * Improvement from baseline in disease activity as measured by BILAG-2004. Improvement is defined as a reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥ 1 new BILAG-2004 A or ≥ 2 new BILAG 2004 B. * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \> 0 points in SLEDAI-2K. * No worsening from baseline in the patient's lupus disease activity, where worsening is defined as an increase ≥ 0.30 points on a 3-point PGA VAS.
Time frame: At week 52
Time to first BICLA response sustained through Week 52
Time from first dose to first BICLA response that is consecutively maintained through Week 52
Time frame: Baseline through to Week 52
BICLA response with maintained low (or reduced) use of oral corticosteroid (OCS)
Response is defined by being a BICLA responder at Week 52 and having maintained low (or reduced) OCS use through Week 52. Maintained OCS use is defined as follows: * If baseline OCS ≥ 10 mg/day an OCS dose of ≤ 7.5 mg/day prednisone or equivalent must be achieved by Week 40 and an OCS dose ≤ 7.5 mg/day prednisone or equivalent must be maintained from Week 40 to Week 52. * If baseline OCS \< 10 mg/day, OCS dose at Week 40 must be less than or equal to OCS dose at baseline, with no increase from Week 40 OCS dose between Week 40 and Week 52.
Time frame: At week 52
Time to flare
Flare defined as either 1 or more BILAG 2004 A or 2 or more BILAG 2004 B compared to previous visit
Time frame: Baseline through to Week 52
Maintained oral corticosteroid (OCS) reduction among patients with baseline OCS ≥10 mg/day.
Achieving maintained OCS reduction through Week 52 is defined by meeting all of the following criteria: * Achieve an OCS dose of ≤ 7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤ 7.5 mg/day prednisone or equivalent from Week 40 to Week 52 * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
Time frame: At week 52
Annualized flare rate
Flare defined as either 1 or more BILAG 2004 or 2 or more BILAG2004 B compared to previous visit
Time frame: Baseline through to Week 52
SRI4
Proportion of patients achieving a SRI of ≥ 4 (SRI\[4\]) response at Week 52, defined by meeting all of the following criteria: Reduction from baseline of ≥ 4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG 2004 B items compared to baseline using BILAG-2004 No worsening from baseline in the patients' lupus disease activity, where worsening is defined by an increase ≥ 0.30 points on a 3-point PGA VAS.
Time frame: At week 52
Adverse Event Overview
Overview of AEs, SAEs and AESIs
Time frame: Up to 2 years 4 months
Showing the first 100 of 140 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Aug 2025, 50 months.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 50 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →